Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences. NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.



Presentation Details:

Event: Morgan Stanley 18th Annual Global Healthcare Conference

Date: Thursday, September 17, 2020

Time: 8:45 a.m. ET

Event: Cantor Fitzgerald Virtual Global Healthcare Conference

Date: Thursday, September 17, 2020

Time: 10:00 a.m. ET

Live webcasts from the Morgan Stanley and Cantor fireside chats will be accessible through the Investors section of the Companyâ€™s website at www.zentalis.com . Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals .

Investor Contact:

Thomas Hoffmann

Solebury Trout

1.646.378.2931

thoffmann@soleburytrout.com